HHS 503A peptide policy (October 28, 2026): what changed and what did not

Published October 29, 2026. Last checked November 1, 2026. Information only, not medical advice.

Cheapest sermorelin on our chart

Tied at $99 a month: CoreAge Rx, Embody, Lttl, Strut Health and Villas Health.

  1. CoreAge Rx logoCoreAge Rxfrom $99 a month, no membership fee. No long-term contractSermorelin injectionChecked November 21, 2026 on CoreAge Rx's own pageCheck price at CoreAge Rx →
  2. Embody logoEmbody$99 a month, after a $49 first monthSermorelin injectionChecked November 21, 2026 on Embody's own pageCheck price at Embody →
  3. Lttl logoLttlfrom $99 a month, visits included. The plan is set at checkoutSermorelin injectionChecked November 21, 2026 on Lttl's own pageCheck price at Lttl →
  4. Strut Health logoStrut Health$99 a month, on auto-refillSermorelin lozengeChecked November 21, 2026 on Strut Health's own pageCheck price at Strut Health →
  5. Villas Health logoVillas Health$99 a month, monthly subscription; $119 as a one-time purchaseSermorelin injectionChecked November 21, 2026 on Villas Health's own pageSee prices

Prices checked by The Pep Chart on , from each program's own page. How we check prices | How we make money

This is an enforcement discretion policy, not FDA approval. The Federal Register published it on October 30, 2026 (91 FR 68526, document 2026-22192). The notice calls the policy a draft and takes written comments for 2 weeks.

What the policy says

On October 28, 2026, HHS filed a notice with the Federal Register announcing an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (document 2026-22192, docket HHS-OASH-2026-0496). The Federal Register published it on October 30, 2026. The notice says HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician" that compounds with a peptide on the policy's Appendix A.

HHS gives its reason in one line: it sees "significant interest in the use of these peptides in compounding given the lack of availability of approved products." The policy is interim. It runs while the FDA writes the 503A bulks list, the list of raw ingredients pharmacies may compound with, through rulemaking. The FDA Law Blog reads it as lasting until each peptide is ruled in or out of that list.

The six peptides

Appendix A names six: the six the FDA's compounding advisory committee voted for at its July 2026 meeting, according to the FDA Law Blog. Appendix B holds each one to a named form and a set route.

  • BPC-157: BPC-157 acetate, injection, oral and topical forms.
  • TB-500: TB-500 acetate, injection only.
  • MOTS-c: MOTS-c acetate, injection only.
  • Epitalon: Epitalon acetate, injection only, dispensed in intermittent courses.
  • KPV: KPV acetate, topical and oral forms only.
  • Semax: Semax free base, nasal use only.

What it is not

  • Not FDA approval.The notice itself says compounded drugs "are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed."
  • Not a place on the bulks list.The notice says the FDA's future rulemakings "may propose adding some or all of these peptides." The FDA's 503A category lists, updated May 14, 2026, name none of the six.
  • Not binding, and not fixed.The policy "does not establish any rights for any person and is not binding on HHS or the public." HHS may revisit it, in whole or in part, if a safety signal or a product quality problem arises.
  • Not 503B, not research chemicals, not supplements.The notice names state-licensed pharmacies, federal facilities and licensed physicians. It does not name 503B outsourcing facilities, and nothing in it covers a vial sold "for research use only" or a supplement. The FDA Law Blog reports that HHS means the policy as a "more controlled alternative" to that gray market.

What a pharmacy has to do

The HHS policy lists the conditions. A pharmacy compounding one of the six must meet all of them:

  • The raw ingredient comes from a maker registered with the FDA that follows current good manufacturing practice.
  • A certificate of analysis names the maker's site and tests the substance as Appendix B sets out.
  • A repacker, relabeler or reseller in between has checked the maker and its certificate.
  • One peptide per product. No blends.
  • The only device packed with it is a syringe cleared by the FDA under 510(k).
  • Serious adverse events and quality problems are reported to the FDA's MedWatch program.
  • The label reads: "This is a compounded drug product. Not for resale."

How to check a seller

The rules fall on the pharmacy, not on the website that takes your order. Section 503A covers a drug compounded "for an identified individual patient based on the receipt of a valid prescription order." Five things you can check before you pay:

  1. The site names the pharmacy that fills the order.
  2. That pharmacy holds a license from its state board of pharmacy.
  3. A prescriber reviews you and writes a prescription. A seller that ships one of the six without one is outside 503A.
  4. The label carries the line "This is a compounded drug product. Not for resale."
  5. The site shows up in LegitScript's certification search.

Our peptide seller checklist runs the checks a website can answer (pharmacy named, prescription, LegitScript) on every program on The Pep Chart, adds FDA warning letters, and links a source for each answer.

What happens next

The Federal Register published the notice on October 30, 2026. Comments are open until 2 weeks after that date, through regulations.gov on docket HHS-OASH-2026-0496. That makes the deadline about November 13, 2026 (ESTIMATE: our count from the notice, because the docket showed no date when we read it). HHS says its own website carries the most current version of the policy. The FDA Law Blog adds that one question is still open: whether states will follow it.

115 public comments had been posted by November 13, 2026. Our commentary on the notice sets out what the docket and our price data show.

CJC-1295, ipamorelin and GHK-Cu

None of the three is in Appendix A, so the policy does not cover them. The FDA lists CJC-1295 among substances that were in Category 2, its list of substances that may present significant safety risks, before their nominations were withdrawn, and says it has identified serious adverse events with it. Ipamorelinacetate has been in Category 2 under the FDA's 503B interim policy since September 29, 2023. GHK-Cu for injection is on the same withdrawn list.

Sources

Cite this page

Permalink: https://thepepchart.com/fda-peptide-rules/hhs-503a-peptide-policy/

Suggested citation: The Pep Chart. "HHS 503A peptide policy (October 28, 2026): what changed and what did not." October 29, 2026. https://thepepchart.com/fda-peptide-rules/hhs-503a-peptide-policy/

Free to quote and chart with a credit link. The terms are on reuse our data, and reporters can start on the press page.

FDA status of every peptide we track